anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 40
Group description: Dexamethasone ophthalmic insert, 0.4mg intracanalicular insert in the lower punctum on the day of surgery in the OR.
Eligibility criteria:
Inclusion Criteria:

Subjects will be eligible for study participation if they:

Are planning to undergo non-complicated CCI CE/PCIOL in one or both eyes with or without iStent/Hydrus/Goniotomy.
Are willing and able to comply with clinic visits and study related procedures.
Are willing and able to sign the informed consent form.
Not pregnant.

Exclusion Criteria:

Subjects are not eligible for study participation if they:

Are currently being treated with corticosteroid implant (i.e. Ozurdex).
Have a history of herpes simplex virus keratitis or present active bacterial, viral, or fungal keratitis in either eye.
Have a history of complete punctal occlusion in one or both punctum.
Currently use topical ophthalmic steroid medications.
Are unwilling or unable to comply with the study protocol.
Are determined by the Investigator to not be included for reasons not already specified (e.g., systemic, behavioral, or other ocular disease/abnormality) or if the health of the subject or the validity of the study outcomes may be compromised by the subject's enrollment.
Have active infectious systemic disease.
Have active infectious ocular or extraocular disease.
Have unobstructed nasolacrimal duct in the study eye(s) (dacrocystitis).
Have known hypersensitivity to dexamethasone or are a known steroid responder.
Have a history of ocular inflammation or macular edema.
Are currently being treated with immunomodulating agents in the study eye(s).
Are currently being treated with immunosuppressants an/or oral steroids.
Are Pregnant or breast-feeding or wish to become pregnant during the length of study participation.
Intervention: Macitentan
Trial phase: Phase 4
ATC code: C02KX04 | C02KX54
SMILES: CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: A consecutive subset of eligible patients based on inclusion/exclusion criteria will receive a 1-week course of Macitentan (10 mg po daily) prior to their routine 1-year coronary angiogram (7th and final dose of Macitentan will occur on the day of the angiogram).

Macitentan: Macitentan is a nonselective endothelin-receptor antagonist (ERA) that is approved for use in pulmonary arterial hypertension (PAH); the use of Macitentan in post-heart transplant patients is considered investigational.
Eligibility criteria:
Inclusion Criteria:

1) New heart transplant recipients already enrolled into a prospective cohort (parent) study
1a) Underwent baseline coronary angiography within the first 4 months of heart transplantation
1b) Have yet to complete 1-year coronary angiogram
2) ≥18 years old
3) Have a serum creatinine < 2.0 mg/dL (to minimize risk of contrast-induced nephropathy)
4) Able to provide informed written consent.

Exclusion Criteria:

1) Multi-organ transplant
2) Transplant-related complications and comorbidities that preclude the ability to safely perform an invasive coronary evaluation in the cardiac catheterization laboratory
3) Pregnant women due to possible fetal harm; all women of childbearing potential must have a negative pregnancy test within 1 week of starting Macitentan, and 30 days after completing the one-week course of Macitentan.
4) Patients who are taking potent CYP3A4 inhibitors (e.g. ketoconazole, ritonavir) as these drugs can expose one to higher levels of macitentan
5) Cirrhosis or baseline liver function tests (AST/ALT) > 3x the upper limit of normal
Intervention: Ketamine
Trial phase: Phase 4
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Drug administration: A single dose of ketamine 0.3 mg/kg IV over 15 minutes. Time drug given will be documented Data obtained prior to med administration and then following medication administration at intervals of 15, 30, 60 and 120 minutes

Record vital signs (HR, B/P, resp rate, O2 sat)

Obtain and assess pain response scores

Pain Numerical Rating Score (NRS - 0-10)
Richmond Agitation Sedation Scale (RASS)
Side Effect Rating Scale for Dissociative Anesthesia (SERSDA)
Record any airway interventions required? If yes what? new supplemental O2/BVM/intubation, jaw thrust
Record any rescue meds, dose and time (Rescue medication - Fentanyl):
1 mcg/kg IV fentanyl (0.5 mcg/kg if age >55 yrs)
Defined as rescue if given <30 min post study intervention for pain score >5 or patient requesting additional medication.
Patient pain satisfaction score at discharge

Ketamine: This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
Eligibility criteria:
Inclusion Criteria:

Ages ≥ 18 years.
Able to speak and understand English.
RSE requiring IV pain medication for NRS pain score > 5.
No allergy to ketamine or fentanyl.
Ability to provide informed consent.
≤ 24 hours from envenomation.

Exclusion Criteria:

Pregnant or lactating.
Prisoners.
Refugees.
History of schizophrenia.
Clinically intoxicated.
On buprenorphine therapy.
History of uncontrolled hypertension
Increased intracranial pressure
Systemic envenomation
Intervention: CO-TRIMOXAZOLE
Trial phase: Phase 1 | Phase 2
ATC code: J01EE01
SMILES: COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC.Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Suspension with the equivalent of one DS TMP-SMX by mouth every 12 hours for 10 days

Trimethoprim Sulfamethoxazole: Receipt of suspension with the equivalent of one DS TMP-SMX by mouth every 12 hours for 10 days
Eligibility criteria:
Inclusion Criteria:

Carries the diagnosis of COPD and admitted for and admitted with AECOPD to Beaumont, Royal Oak (AECOPD requires increased cough, increased sputum production, and shortness of breath +/- increased oxygen needs from baseline)
Able to produce a sputum sample
Men or women, age ≥ 40 and < 90
Previously enrolled in the EPIC Study and positive for Pneumocystis jirovecii detected in their sputum
Currently treated with steroids
Kidney function not severely impaired (CrCl ≥ 60)
AST and ALT ≤5x upper limit of normal
Willing and able to consent to the study

Exclusion Criteria:

Current diagnosis of pneumonia or COVID-19
Allergy or hypersensitivity to trimethoprim-sulfamethoxazole
Current ICU admission or mechanical ventilation
Active cancer or chemotherapy (except non-melanoma skin cancer)
Other potentially confounding pulmonary diagnosis
HIV, leukopenia, neutropenia, or other immunosuppressive condition or current use of immunosuppressive medications
Presence of gastrointestinal tract abnormalities that would prevent absorption of medications
Patients with concomitant infection requiring antibiotics active against Pneumocystis jirovecii
Concomitant use of coumadin, phenytoin, pioglitazone, repaglinide, rosiglitazone, glipizide or glyburide
Megaloblastic anemia due to folate deficiency
Pregnancy
Life expectancy less than 3 months
Intervention: Methylprednisolone
Trial phase: Phase 4
ATC code: D07AA01 | D07CA02 | D10AA02 | H02AB04 | H02BX01 | S01CA08 | S03CA07
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 421
Group description: subacromial or glenohumeral shoulder injection

Methylprednisolone (MPA): injection into subacromial or glenohumeral space with MPA
Eligibility criteria:
Inclusion Criteria:

Subacromial or glenohumeral shoulder pain to be treated with steroid injection
Fluent in written and oral English
Willing and able to provide written consent
Willing to complete follow up pain scores (visual analog score)

Exclusion Criteria:

Unable to provide written consent
Chronic pain syndrome
Unwilling to complete follow up pain scores (visual analog score)
Intervention: Kenalog
Trial phase: Phase 4
SMILES: CC1(C)OC2CC3C4CCC5=CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 421
Group description: subacromial or glenohumeral shoulder injection

Triamcinolone Acetonide (TA): injection into subacromial or glenohumeral space with TA
Eligibility criteria:
Inclusion Criteria:

Subacromial or glenohumeral shoulder pain to be treated with steroid injection
Fluent in written and oral English
Willing and able to provide written consent
Willing to complete follow up pain scores (visual analog score)

Exclusion Criteria:

Unable to provide written consent
Chronic pain syndrome
Unwilling to complete follow up pain scores (visual analog score)
Intervention: Phenylephrine
Trial phase: Phase 4
ATC code: C01CA06 | R01AA04 | R01AB01 | R01BA03 | R01BA53 | S01FB01 | S01FB51 | S01GA05 | S01GA55
SMILES: CNC[C@H](O)c1cccc(O)c1
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Phenylephrine (1ug/kg) administered once the child is under anesthesia.
Eligibility criteria:
Inclusion Criteria:

Patients presenting for cardiac catheterization procedure with a diagnosis of PAH either by previous cardiac catheterization or echocardiography

Exclusion Criteria:

Children presenting for cardiac catheterization who do not have PAH;
Children with PAH but with intracardiac shunts
Intervention: Pituitrin
Trial phase: Phase 4
SMILES: NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Arginine Vasopressin (1ug/kg) administered once the child is under anesthesia.
Eligibility criteria:
Inclusion Criteria:

Patients presenting for cardiac catheterization procedure with a diagnosis of PAH either by previous cardiac catheterization or echocardiography

Exclusion Criteria:

Children presenting for cardiac catheterization who do not have PAH;
Children with PAH but with intracardiac shunts
Intervention: Epinephrine
Trial phase: Phase 4
ATC code: A01AD01 | B02BC09 | C01CA24 | R01AA14 | R03AA01 | R03AK01 | S01EA01 | S01EA51
SMILES: CNCC(O)c1ccc(O)c(O)c1
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Epinephrine (0.5-1ug/kg) administered once the child is under anesthesia.
Eligibility criteria:
Inclusion Criteria:

Patients presenting for cardiac catheterization procedure with a diagnosis of PAH either by previous cardiac catheterization or echocardiography

Exclusion Criteria:

Children presenting for cardiac catheterization who do not have PAH;
Children with PAH but with intracardiac shunts
Intervention: Flutamide
Trial phase: Phase 4
ATC code: L02BB01
SMILES: CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: Participants will receive pregabalin orally 75mg twice daily x 7 days prior to surgery, 150mg twice daily x 7 days after surgery, followed by 75mg twice daily x 7 days. Then Stop.
Eligibility criteria:
Inclusion Criteria:

Patients undergoing native joint unilateral TKA due to Grade 3-4 primary osteoarthritis
Patients with score of at least 40 on Central Sensitization Inventory
Patients who will complete PT within the U of Iowa Health Care system
Patients who have been nonsmokers for > 2 years
Patients between the ages of 50 and 85

Exclusion Criteria:

Patients already taking pregabalin or had an adverse effect with pregabalin in the past
Patients indicated for joint revision surgery
Patients taking at least 30 morphine milligram equivalents per day for the past 1 month
Patients with an estimate GFR < 30 ml/min
Patients who do not have an understanding of English
Patients who are pregnant or women of child-bearing years
Patients who are prisoners
Patients who score < 40 on the CSI
Patients who answer Yes to any questions on the Columbia Suicide Severity Rating Scale or express suicidal ideation
Intervention: Remdesivir
Trial phase: Phase 4
ATC code: J05AB16
SMILES: CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 265
Group description: Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes

Remdesivir: antiviral drug
Eligibility criteria:
Inclusion Criteria:

age more than 12 years old.
weight not less than 40 kg.
Moderate, sever or critical COVID-19 disease as defined by WHO.
PCR- confirmed patients to be Positive before inclusion.

Exclusion Criteria:

history of hypersensitivity or infusion related reactions after administration of monoclonal antibodies.
prior use of standard antiviral therapy (remedsvir or favipravir).
Current use of controversial antiviral therapy (hydroxychloroquine, ivermectin, nitazoxanide, oseltemavir, acyclovir, ribavirine, lopinvir/rotinvir, sofosfbuvir, decltasevir, semipirvir, azithromycin).
patients expected to die within 48 hours.
Intervention: Favipiravir
Trial phase: Phase 4
ATC code: J05AX27
SMILES: NC(=O)c1nc(F)cnc1O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 265
Group description: Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) orally or in Ryle tube / 12 hours day 2-10 (maintenance dose): 800 mg (4 tablets) orally or in Ryle tube / 12 hours

Favipiravir: antiviral drug
Eligibility criteria:
Inclusion Criteria:

age more than 12 years old.
weight not less than 40 kg.
Moderate, sever or critical COVID-19 disease as defined by WHO.
PCR- confirmed patients to be Positive before inclusion.

Exclusion Criteria:

history of hypersensitivity or infusion related reactions after administration of monoclonal antibodies.
prior use of standard antiviral therapy (remedsvir or favipravir).
Current use of controversial antiviral therapy (hydroxychloroquine, ivermectin, nitazoxanide, oseltemavir, acyclovir, ribavirine, lopinvir/rotinvir, sofosfbuvir, decltasevir, semipirvir, azithromycin).
patients expected to die within 48 hours.
Intervention: Bis(choline)tetrathiomolybdate
Trial phase: Phase 1
SMILES: C[N+](C)(C)CCO.C[N+](C)(C)CCO.S=[Mo]=S.[SH-].[SH-]
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 12
Group description: All Japanese participants received a single dose of ALXN1840 15 mg in Dosing Period 1 and received a single dose of ALXN1840 60 mg in Dosing Period 2.
Eligibility criteria:
Key Inclusion Criteria: - Body weight ≤80 kilograms (kg) and body mass index (BMI) within the range 18-25 kg/m^2, inclusive, at screening. - Negative serum pregnancy test. - Female participants of childbearing potential and male participants with a female spouse or partner of childbearing potential must be willing to follow protocol-specified contraception guidance starting at least one menstrual cycle before first study drug administration and continuing for up to 3 months after the end of systemic exposure of the study drug (that is, 3 months after end of study visit).

Key Exclusion Criteria: - Current or recurrent/chronic disease (for example, cardiovascular, hematological, neurological, endocrine, immunological, rheumatological, renal, hepatic, or gastrointestinal (GI) or other conditions) that or could affect clinical assessments or clinical laboratory evaluations. - Current or relevant history of physical or psychiatric illness that are not stable or may require a change in treatment, use of prohibited therapies during the study or make the participant unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the study drug or study procedures. - Any other significant disease or disorder which, in the opinion of the Investigator, may put the participant at risk. - History of significant allergic reaction (for example, anaphylaxis or angioedema) to any product (for example, food, pharmaceutical). - Use of prescription medications (excluding oral contraceptives) within 14 days prior to dosing on Day 1, except with prior approval of Alexion. - Use of non-prescription/ over-the-counter medications including vitamins and dietary or herbal supplements, within 7 days prior to dosing on Day 1. - Donated or lost 400 milliliters (mL) blood or more within the last 16 weeks preceding the first day of dosing.
Intervention: FLUTICASONE FUROATE
Trial phase: Phase 3
ATC code: R01AD12 | R03AK10 | R03AL08 | R03BA09
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)c3ccco3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 656
Group description: Fluticasone is a self-administered inhaled drug. Participants will self-administer 200 µg (1 blister) of fluticasone once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the study drug through the mouthpiece.

Fluticasone: Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
Eligibility criteria:
Inclusion Criteria:

Completed Informed Consent
Age ≥ 30 years old
Confirmed SARS-CoV-2 infection by any authorized or approved polymerase chain reaction (PCR) or antigen test collected within 10 days of screening
Two or more current symptoms of acute infection for ≤7 days. Symptoms include the following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal symptoms, new loss of sense of taste or smell

Exclusion Criteria:

Prior diagnosis of COVID-19 infection (> 10 days from screening)
Current or recent (within 10 days of screening) hospitalization
Current use of study drug or study drug/device combination*
Known allergy/sensitivity or any hypersensitivity to components of the study drug or placebo*
Known contraindication(s) to study drug including prohibited concomitant medications*

[*If only one study drug appendix is open at the time of enrollment. If multiple study drug appendices are open, a participant may opt-out of any study drug appendix or be excluded from any study drug appendix based on contraindications listed in the study drug appendix, current use of study drug, or known allergy/sensitivity/hypersensitivity and still remain eligible for the remaining study drug appendices.]

Arm-specific exclusion criteria

Severe hypersensitivity to milk proteins
Currently prescribed or use within 30 days of inhaled or systemic steroids
Moderate to severe hepatic impairment, defined as Child-Pugh B or C
Nursing mothers
Pregnancy
Intervention: Rosuvastatin Calcium
Trial phase: Phase 4
SMILES: CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1C=CC(O)CC(O)CC(=O)[O-].CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1C=CC(O)CC(O)CC(=O)[O-].[Ca+2]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: 1) ordering a lipid panel during the index ED encounter and 30-days (+/- 5 business days) after ED discharge, 2) completion of the Pooled Cohort Equations by the patient's ED provider at the index visit, and 3) starting medical therapy (moderate- or high-intensity statin/ rosuvastatin) in the ED

moderate- or high-intensity statin/ rosuvastatin: moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)
Eligibility criteria:
Inclusion Criteria:

Emergency Department (ED) patients with chest pain
40-75 years old
a low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL on an ED lipid panel or have known diabetes or Atherosclerotic Cardiovascular Disease (ASCVD)

Exclusion Criteria:

Subject unwilling to take study medication
Pregnancy or breastfeeding
Inability to take study medication or, in the opinion of the Investigators/subject's doctors unsuitable for study participation
ST-Segment Elevation Myocardial Infarction (STEMI) Activation
ST-Segment Depression >1 mm
On a Lipid Lowering Agent (Statin, PCSK9 Inhibitor, Bempedoic Acid, Ezetimibe, Inclisiran)
Unstable Vitals (Blood Pressure (BP) <90, Heart Rate (HR) >120 or <50, O2 sat <90%)
Statin Intolerance
High-sensitivity Troponin I ≥100 ng/L
End-Stage Renal Disease (ESRD) and/or glomerular filtration rate (GFR) <30 mL/min/1.73 m2
Liver Cirrhosis
Hospitalization
Life Expectancy <1 Year
Transfer from Another Hospital
Prisoner
Non-English Speaking